仙壇股份(002746.SZ)半年度淨利潤預降53.33%-60.51%
格隆匯7月11日丨仙壇股份(002746.SZ)公佈,預計2021年半年度歸屬於上市公司股東的淨利潤1.1億元-1.3億元,同比下降53.33%-60.51%。
2020年一季度白羽肉雞延續了2019年的好行情,自二季度之後行情開始回落,直至年底行情跌至谷底企穩。2021年上半年以來行情開始逐步往上,但相比2020年上半年的基數,公司2021年上半年雞肉產品的平均銷售價格仍低於2020年同期。受雞肉產品價格變動的影響,公司2021年上半年的銷售收入同比下降。
受玉米和豆粕等大宗原材料價格上漲的影響,公司2021年上半年的銷售成本同比上升。
綜上因素影響,公司2021年上半年的淨利潤同比減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.